Myelo Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $18.9M

Myelo Therapeutics General Information

Description

Developer of medical countermeasure drugs designed to treat acute radiation syndrome, reducing radiation-induced myelosuppression after nuclear accidents or attack scenarios. The company develops a small molecule-based oral therapy that is effective in reducing the risk of chemotherapy-induced myelosuppression and radiation in patients across various cancer types and radio-chemotherapy regimens, enabling physicians to improve patient lives.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Rheinsberger Strasse 7
  • 10115 Berlin
  • Germany
+49 030
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Vertical(s)
Corporate Office
  • Rheinsberger Strasse 7
  • 10115 Berlin
  • Germany
+49 030

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Myelo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 15-Dec-2022 $18.9M Completed Clinical Trials - Phase 2
7. Grant 04-Jun-2021 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 26-Jun-2020 Completed Clinical Trials - Phase 2
5. Grant 11-May-2020 Completed Clinical Trials - Phase 2
4. Early Stage VC 12-Jun-2017 Completed Clinical Trials - Phase 2
3. Accelerator/Incubator 13-Jan-2017 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 15-Dec-2015 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 13-Apr-2013 Completed Startup
To view Myelo Therapeutics’s complete valuation and funding history, request access »

Myelo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical countermeasure drugs designed to treat acute radiation syndrome, reducing radiation-induced myelosu
Drug Discovery
Berlin, Germany
4 As of 2025

Lexington, MA
 

Thousand Oaks, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Myelo Therapeutics Competitors (3)

One of Myelo Therapeutics’s 3 competitors is Partner Therapeutics, a Venture Capital-Backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Partner Therapeutics Venture Capital-Backed Lexington, MA
Amgen Formerly PE-Backed Thousand Oaks, CA
Emergent BioSolutions Corporation Gaithersburg, MD
You’re viewing 3 of 3 competitors. Get the full list »

Myelo Therapeutics Patents

Myelo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3113478-A1 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation Pending 25-Sep-2018
EP-3856175-A1 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation Pending 25-Sep-2018
US-20210275498-A1 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation Pending 25-Sep-2018
WO-2020064832-A1 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation Inactive 25-Sep-2018
US-20050180953-A1 Peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[n-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (dicarbamine (reg) ) Active 28-Feb-2002 A61K31/195
To view Myelo Therapeutics’s complete patent history, request access »

Myelo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Myelo Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eckert Life Science Accelerator Accelerator/Incubator Minority
IBB Ventures Venture Capital Minority
IDrug Venture Capital Minority
Investitionsbank Berlin Investment Bank Minority
National Institute Of Allergy and Infectious Diseases Government
You’re viewing 5 of 9 investors. Get the full list »

Myelo Therapeutics FAQs

  • When was Myelo Therapeutics founded?

    Myelo Therapeutics was founded in 2013.

  • Where is Myelo Therapeutics headquartered?

    Myelo Therapeutics is headquartered in Berlin, Germany.

  • What is the size of Myelo Therapeutics?

    Myelo Therapeutics has 4 total employees.

  • What industry is Myelo Therapeutics in?

    Myelo Therapeutics’s primary industry is Drug Discovery.

  • Is Myelo Therapeutics a private or public company?

    Myelo Therapeutics is a Private company.

  • What is the current valuation of Myelo Therapeutics?

    The current valuation of Myelo Therapeutics is .

  • What is Myelo Therapeutics’s current revenue?

    The current revenue for Myelo Therapeutics is .

  • Who are Myelo Therapeutics’s investors?

    Eckert Life Science Accelerator, IBB Ventures, IDrug, Investitionsbank Berlin, and National Institute Of Allergy and Infectious Diseases are 5 of 9 investors who have invested in Myelo Therapeutics.

  • Who are Myelo Therapeutics’s competitors?

    Partner Therapeutics, Amgen, and Emergent BioSolutions are competitors of Myelo Therapeutics.

  • When was Myelo Therapeutics acquired?

    Myelo Therapeutics was acquired on 15-Dec-2022.

  • Who acquired Myelo Therapeutics?

    Myelo Therapeutics was acquired by Eckert & Ziegler.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process